ELIVA CREASE GEL

Research indicates that 3-O-ethyl ascorbic acid delivered via dissolving microneedles achieved 17.25% cumulative transdermal delivery and significantly reduced visible signs of photoaging including wrinkles and erythema in a UV-induced aging model. Studies suggest microneedle delivery systems enhanced ETVC bioavailability compared to aqueous solutions, with improved skin elasticity and hydration observed in human subjects.

Study authors not specified in abstract International Journal of Biological Macromolecules. 2026. PubMed →

Research indicates that 3-O-ethyl ascorbic acid demonstrated stronger regenerative effects on multiple skin cell types (keratinocytes, melanocytes, fibroblasts) compared to standard ascorbic acid following UVA exposure. Studies suggest the derivative showed consistent protective results across multiple viability assessment methods, supporting potential cellular protection mechanisms in healthy skin cells.

Study authors not specified in abstract Biomedicine & Pharmacotherapy. 2024. PubMed →

Research indicates that 3-O-ethyl ascorbic acid may help support kinase-dependent signaling recovery in UVB-damaged keratinocytes by reducing expression of stress-response kinases and limiting lipid peroxidation damage. Studies suggest the compound may help restore skin cell proteome stability following UV exposure, with effects on ERK1/2, MAP kinase, and IKK pathways.

Study authors not specified in abstract Scientific Reports. 2024. PubMed →

Research indicates that lipid-based gel formulations enhanced 3-O-ethyl L-ascorbic acid retention in the skin compared to standard delivery, with bigel systems achieving greater epidermal penetration. Studies suggest the lipophilic nature of formulation vehicles significantly influences ingredient distribution, with enhanced antioxidant efficacy demonstrated in skin tissue models.

Study authors not specified in abstract Pharmaceutics. 2024. PubMed →

Research indicates that 3-O-ethyl ascorbic acid interacts with skin lipid structures and may support the stability of phosphatidylinositol monolayers. Studies suggest the compound's antioxidant properties may enhance the efficacy of antimicrobial peptides, potentially supporting skin microbiome-related concerns.

Study authors not specified in abstract International Journal of Molecular Sciences. 2024. PubMed →

Large database analysis examining niacinamide's potential role in skin cancer prevention through supplementation.

Not specified in abstract provided Journal of the American Academy of Dermatology. 2026. PubMed →

Research indicates that neutral pH (7.4) formulations increase niacinamide skin permeation approximately twofold compared to acidic pH (5.0), with corresponding changes in stratum corneum electrical properties facilitating enhanced transdermal delivery. Studies employed Franz cell diffusion experiments and electrical impedance spectroscopy using human skin models to characterize pH-dependent permeation mechanisms.

Not specified in abstract provided Scientific Reports. 2026. PubMed →

Research indicates that dissolving microneedle patches containing niacinamide exhibit greater skin-lightening effects than traditional topical formulations for treating melasma and post-inflammatory hyperpigmentation. Clinical studies have validated safety and efficacy with minimal adverse effects when using advanced transdermal delivery systems.

Not specified in abstract provided Recent Advances in Drug Delivery and Formulation. 2026. PubMed →

Systematic umbrella review evaluating nutritional supplements including niacinamide for primary prevention of skin diseases across 9,229 participants, examining preventive effects against ultraviolet radiation-induced skin pathology and other dermatological conditions.

Not specified in abstract provided Preventive Nutrition and Food Science. 2026. PubMed →

Research comparing glabridin with niacinamide as recognized inhibitor of melanosome transfer in UVB-irradiated co-culture systems demonstrated complementary mechanisms for reducing melanin transfer from melanocytes to keratinocytes through dendrite suppression pathways.

Not specified in abstract provided Pharmaceuticals (Basel, Switzerland). 2026. PubMed →